We have recently developed the first genetic mouse model for therapy and analysis of metastatic prostate cancer. Now we can test if and how modern concepts of cancer evolution can outperform the 80-year-old standard of care- hormone deprivation therapy-and turn lethal prostate cancer into a curable disease.
Lloyd Trotman’s recent research path begins at his discovery some years ago that the loss of a single copy of a master tumor suppressing gene called PTEN is sufficient to permit tumors to develop in animal models of prostate cancer. His team later found that complete loss of PTEN paradoxically triggers senescence, an arrested state that delays or blocks cancer development in affected cells. These findings explained why many patients only display partial loss of this tumor suppressor when diagnosed with prostate cancer. Now the team is researching ways to restore the PTEN protein levels in these patients. This therapeutic approach could slow disease progression and thus greatly reduce the need for surgical removal of the prostate or similar drastic interventions that carry the risks of incontinence and impotence. Their second approach to combat prostate cancer is to model the lethal metastatic disease in genetically engineered mice. They are developing a novel approach that allows for quick generation and visualization of metastatic disease. The efficacy of existing and novel late-stage therapies, such as antihormonal therapy, can then be tested and optimized in these animals. At the same time, the Trotman lab is exploring the genome alterations associated with metastatic disease and with resistance to therapy. To this end, they use single- and multicell genome sequencing techniques developed at CSHL by Drs. Wigler and Hicks.
The prostate cancer cell that got away
November 16, 2021
Like finding a needle in a haystack, CSHL scientists can now track prostate cancer in mice from its single cell start and as it spreads.
CSHL Ph.D. program: Graduating class of 2021
August 22, 2021
The CSHL School of Biological Sciences awarded Ph.D. degrees to seven students this year, who describe some of their experiences.
CSHL Association holds its annual meeting
January 29, 2021
The Cold Spring Harbor Laboratory Association welcomes four new directors and thanks three retiring ones.
Cold Spring Harbor Laboratory: Science is hope
December 21, 2020
The Laboratory is a leading research center for genetics, cancer, plant biology, quantitative biology, and neuroscience.
A science career path: Jason Williams
April 24, 2020
He is now a leader at the DNA Learning Center, the place that taught him to love biology in high school.
Congressman Suozzi honors Regeneron scholars at CSHL
February 26, 2020
Congressman Tom Suozzi congratulated Regeneron semi-finalists, including two Partners for the Future, at a ceremony hosted at CSHL.
Fresh insights into prostate cancer surprise Movember crowd
November 22, 2019
For a special “Movember” edition of Cocktails and Chromosomes, Dr. Lloyd Trotman explained what his lab is doing to understand deadly prostate cancers.
Movember with Lloyd Trotman—A Cocktails and Chromosomes talk about prostate cancer
November 19, 2019
In this Movember edition of Cocktails & Chromosomes, learn how new concepts of cancer evolution could turn prostate cancer into a curable disease.
Event: Cocktails & Chromosomes – The Movember edition
August 27, 2019
Join us for the next edition of Cocktails & Chromosomes, featuring CSHL Professor Lloyd Trotman, Ph.D.
Enzyme PHLPP2 could be a viable drug target for treating prostate cancer
May 15, 2019
Researchers have identified an enzyme called Phlpp2 as an attractive drug target for treating prostate cancer.
Combined whole-organ imaging at single-cell resolution and immunohistochemical analysis of prostate cancer and its liver and brain metastases.
16 Nov 2021 | Cell Reports | 37(7):110027
Taranda, Julian, Mathew, Grinu, Watrud, Kaitlin, El-Amine, Nour, Lee, Matthew, Elowsky, Corey, Bludova, Anastasiia, Escobar Avelar, Sintia, Nowak, Dawid, Wee, Tse-Luen, Wilkinson, John, Trotman, Lloyd, Osten, Pavel
4 Jul 2021 | Cancer Drug Resistance | 4:745-754
Lyons, Scott, Plenker, Dennis, Trotman, Lloyd
7 Sep 2020 | Journal of Experimental Medicine | 217(9)
Oni, T, Biffi, G, Baker, L, Hao, Y, Tonelli, C, Somerville, T, Deschênes, A, Belleau, P, Hwang, C, Sánchez-Rivera, F, Cox, H, Brosnan, E, Doshi, A, Lumia, R, Khaledi, K, Park, Y, Trotman, L, Lowe, S, Krasnitz, A, Vakoc, C, Tuveson, D
Jun 2020 | Journal of Experimental Medicine | 217(6):e20200087
Mathew, G, Trotman, L
16 Apr 2020 | Cell | 181(2):219-222
Monje, M, Borniger, J, D'Silva, N, Deneen, B, Dirks, P, Fattahi, F, Frenette, P, Garzia, L, Gutmann, D, Hanahan, D, Hervey-Jumper, S, Hondermarck, H, Hurov, J, Kepecs, A, Knox, S, Lloyd, A, Magnon, C, Saloman, J, Segal, R, Sloan, E, Sun, X, Taylor, M, Tracey, K, Trotman, L, Tuveson, D, Wang, T, White, R, Winkler, F
9 Dec 2019 | Cold Spring Harbor Perspectives in Medicine
Lee, M, Trotman, L
Docetaxel/cabazitaxel and fatty acid binding protein 5 inhibitors produce synergistic inhibition of prostate cancer growth
29 Oct 2019 | The Prostate
Carbonetti, G, Converso, C, Clement, T, Wang, C, Trotman, L, Ojima, I, Kaczocha, M
16 Sep 2019 | Clinical Cancer Research | 25(23):7162-7174
Froeling, F, Mosur Swamynathan, M, Deschenes, A, Chio, I, Brosnan, E, Yao, M, Alagesan, P, Lucito, M, Li, J, Chang, A, Trotman, L, Belleau, P, Park, Y, Rogoff, H, Watson, J, Tuveson, D
Combined inhibition of tumor suppressors PTEN and PP2A drives anoikis resistance and is associated with therapy relapse in prostate cancer
Jul 2019 | Cancer Research | 79(13S):Meeting Abstract: 3486
Rupp, C, Isomursu, A, Aakula, A, Erickson, A, Li, S, Kaur, A, Shah, P, Pokharel, Y, Trottman, L, Lammerding, J, Rannikko, A, Taimen, P, Mirtti, T, Paatero, I, Ivaska, J, Westermarck, J
15 May 2019 | The Journal of Cell Biology | 218(6):1943-1957
Nowak, D, Katsenelson, K, Watrud, K, Chen, M, Mathew, G, D'Andrea, V, Lee, M, Swamynathan, M, Casanova-Salas, I, Jibilian, M, Buckholtz, C, Ambrico, A, Pan, C, Wilkinson, J, Newton, A, Trotman, L